Rachel Lane
Chief Business Officer at Belharra Therapeutics
San Francisco Bay Area
Overview
Work Experience
Chief Business Officer
2023 - Current
Interim Chief Business Officer
2021 - 2023
Belharra Therapeutics disrupts the drug discovery paradigm with its novel photoaffinity-based chemoproteomics platform.
Raised $50,000,000.00 from Versant Ventures.
Interim Chief Business Officer
2021 - 2024
Board Member
2023 - 2023
Board Observer
2021 - 2023
Kate Therapeutics is a biotechnology company focused on developing next-generation gene therapies for muscle and heart diseases.
Raised $72,775,022.00 from Versant Ventures, UF Innovate Ventures, Westlake Village BioPartners and OUP (Osage University Partners).
Chief Business Officer
2021 - 2023
Board Observer
2020 - 2023
Santa Ana Bio is a biotechnology company focusing on precision immunology for autoimmune and inflammatory diseases.
Raised $176,024,658.00 from Andreessen Horowitz, RTW Investments, Access Biotechnology and Google Ventures.
Principal
2020 - 2023
Versant Ventures caters to the healthcare sector with early and later stage venture, private equity, and debt financing investments.
Board Observer
2021 - 2022
Board Observer
2020 - 2022
iECURE is a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet needs.
Raised $115,000,000.00 from Novo Holdings, Versant Ventures, OrbiMed, LYFE Capital, Versant Ventures and OrbiMed.
Director, Business Development
2019 - 2020
Calico is an Alphabet-founded research and development company whose mission is to harness advanced technologies.
Education
Ph.D.
2004 - 2008
BSc (Hons)
2000 - 2004